# USCI Medical Laboratory Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/usci-medical-laboratory-co

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.scisoon.cn
- Total disclosed funding: $25M
- Latest round: Series A (Jul 1, 2017)
- Investors on record: 3

## About

Established in 2015 and based in Beijing, China, USCI Medical Laboratory Co., Ltd. operates as a genetic testing service provider that focuses on birth defect detection and cancer medical development. The company completed series A funding in July 2017. The company was selected to "the most development potential industries" in January 2018. The company acquired strategic investment from Shenzhen Huada fund in April 2019. Mr. Ye Zhou is the CEO of the company.

The company provides medical health solutions. The business of the company includes disease prevention, prediction, detection, interpretation and intervention. The company's platform passed NextSeq 500/CN500, BGISEQ-500 and MGISEQ-2000. The company's products include tumor diagnosis and treatment series testing products, blood tumor series testing products and eugenics and eugenics series testing products. Tumor diagnosis and treatment series testing products include Youti ® Tumor individualized gene detection, Youxu ® Circulating tumor DNA (ctDNA) detection and Youyi ® Genetic tumor susceptibility gene screening.

The company will put the funding towards instrument and reagent products R&D, registration declaration and production, market layout and expansion in strategic investment.

## Funding rounds

- Series A, Jul 1, 2017, $25M — GTJA Investment Group, K2VC, Citic Guoan Group

## Investors

- GTJA Investment Group (https://capitalatlas.ai/funds/gtja-investment-group) — Series A
- K2VC (https://capitalatlas.ai/funds/k2vc) — Series A
- Citic Guoan Group — Series A